Carmen Mak

2.2k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Carmen Mak is a scholar working on Infectious Diseases, Hepatology and Epidemiology. According to data from OpenAlex, Carmen Mak has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Hepatology and 3 papers in Epidemiology. Recurrent topics in Carmen Mak's work include HIV/AIDS drug development and treatment (4 papers), Hepatitis C virus research (3 papers) and HIV Research and Treatment (2 papers). Carmen Mak is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), Hepatitis C virus research (3 papers) and HIV Research and Treatment (2 papers). Carmen Mak collaborates with scholars based in United States, United Kingdom and France. Carmen Mak's co-authors include Michael P. Manns, Janice K. Albrecht, John G. McHutchison, Thierry Poynard, Keyur Patel, Jean–Jacques Garaud, Jules L. Dienstag, William M. Lee, Christian Trépo and Karen L. Lindsay and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Lancet Oncology.

In The Last Decade

Carmen Mak

11 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C

2002 775 citations John G. McHutchison, Michael P. Manns et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carmen Mak United States	7	894	752	219	198	196	11	1.2k
John Boitnott United States	15	1.2k 1.3×	1.1k 1.4×	173 0.8×	89 0.4×	115 0.6×	20	1.7k
Lisa M. Nyberg United States	16	1.5k 1.7×	1.4k 1.9×	241 1.1×	41 0.2×	86 0.4×	39	1.7k
Andrew J. Muir United States	14	1.2k 1.3×	998 1.3×	218 1.0×	29 0.1×	118 0.6×	35	1.4k
Manuel García–Bengoechea Spain	9	950 1.1×	892 1.2×	237 1.1×	41 0.2×	49 0.3×	15	1.2k
Arnolfo Petruzziello Italy	14	873 1.0×	816 1.1×	106 0.5×	64 0.3×	162 0.8×	24	1.2k
Ziad Younes United States	22	882 1.0×	1.3k 1.7×	199 0.9×	94 0.5×	223 1.1×	67	1.8k
Alessia Ciancio Italy	24	1.8k 2.1×	1.8k 2.4×	180 0.8×	75 0.4×	140 0.7×	101	2.2k
Isabelle Rosa France	17	569 0.6×	613 0.8×	80 0.4×	150 0.8×	42 0.2×	49	972
Shuhei Hige Japan	21	1.5k 1.6×	1.4k 1.9×	93 0.4×	121 0.6×	208 1.1×	66	2.0k
Nathalie Adda United States	18	2.0k 2.2×	1.8k 2.4×	685 3.1×	66 0.3×	133 0.7×	55	2.3k

Countries citing papers authored by Carmen Mak

Since Specialization

Citations

This map shows the geographic impact of Carmen Mak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Mak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Mak more than expected).

Fields of papers citing papers by Carmen Mak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Mak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Mak. The network helps show where Carmen Mak may publish in the future.

Co-authorship network of co-authors of Carmen Mak

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Mak. A scholar is included among the top collaborators of Carmen Mak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Mak. Carmen Mak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Perrin, Steven, Shafeeq Ladha, Nicholas J. Maragakis, et al.. (2024). Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLoS Medicine. 21(10). e1004469–e1004469. 2 indexed citations

Tseng, Jack, et al.. (2021). Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events. Clinical Pharmacokinetics. 60(12). 1557–1567. 7 indexed citations

Long, Georgina V., Jean‐Jacques Grob, Paul Nathan, et al.. (2016). Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. The Lancet Oncology. 17(12). 1743–1754. 212 indexed citations

Grob, Jean‐Jacques, Keith T. Flaherty, Georgina V. Long, et al.. (2016). Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.. Journal of Clinical Oncology. 34(15_suppl). 9534–9534. 5 indexed citations

Sulkowski, Mark, Stanislas Pol, Josep Mallolas, et al.. (2013). Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet Infectious Diseases. 13(7). 597–605. 142 indexed citations

Caseiro, Marcos Montani, Mark Nelson, Ricardo Sobhie Diaz, et al.. (2012). Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials. Journal of Infection. 65(4). 326–335. 33 indexed citations

Girman, Cynthia J., Ekopimo Ibia, Shailendra Menjoge, et al.. (2011). Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials. Drug Information Journal. 45(5). 587–594. 9 indexed citations

Tanaka, Yoko, Carmen Mak, Ekopimo Ibia, et al.. (2011). Points to Consider in Defining Region for a Multiregional Clinical Trial: Defining Region Work Stream in PhRMA MRCT Key Issue Team. Drug Information Journal. 45(5). 575–585. 4 indexed citations

Suleiman, Jamal, Barry S. Zingman, Ricardo Sobhie Diaz, et al.. (2010). Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial. The Journal of Infectious Diseases. 201(4). 590–599. 37 indexed citations

10.

McHutchison, John G., Michael P. Manns, Keyur Patel, et al.. (2002). Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C. Gastroenterology. 123(4). 1061–1069. 775 indexed citations breakdown →

11.

Mak, Carmen, et al.. (2001). Compliance as an Explanatory Variable in Hepatitis-C. Drug Information Journal. 35(4). 1351–1361. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact